Volume 95 Issue 44 | p. 15 | Concentrates
Issue Date: November 6, 2017

Synthetic Genomics boosts RNA vaccines

Department: Business
Keywords: Vaccines, RNA, Synthetic Genomics, replicon, Arcturus Therapeutics

Synthetic Genomics has formed two partnerships to pursue RNA replicon-based vaccines, in which self-replicating RNA molecules encode multiple antigen proteins to produce an immune response. One partner, Arcturus Therapeutics, will share its RNA delivery system for an undisclosed payment plus milestones and royalties. Arcturus and Janssen recently agreed to develop hepatitis B treatments with the RNA delivery technology. Synthetic Genomics will also partner with Ceva Santé Animale to develop livestock vaccines.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment